Company Overview of H3 Biomedicine Inc.
H3 Biomedicine Inc., a biopharmaceutical company, is engaged in the discovery and development of small-molecule drugs to treat cancer. H3 Biomedicine Inc. has a strategic collaboration with Selvita S.A. The company was founded in 2010 and is based in Cambridge, Massachusetts. H3 Biomedicine Inc. operates as a subsidiary of Eisai Inc.
300 Technology Square
Cambridge, MA 02139
Founded in 2010
Key Executives for H3 Biomedicine Inc.
President and Chief Executive Officer
Senior Vice President of Planning and Operations
Compensation as of Fiscal Year 2016.
H3 Biomedicine Inc. Key Developments
H3 Biomedicine Announces Appointment of Tarek Sahmoud as Chief Medical Officer
Jun 1 16
H3 Biomedicine Inc. announced the appointment of Tarek Sahmoud, MD, PhD, as Chief Medical Officer. Prior to joining H3 Biomedicine, Dr. Sahmoud most recently served as Vice President, Oncology Clinical Development and Medical Affairs for the United States business at Boehringer Ingelheim.
H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application
May 11 16
H3 Biomedicine Inc. announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical trials for its lead oncology drug candidate H3B-8800. The compound is an oral and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1), which is being developed by H3 Biomedicine as an anticancer therapeutic agent for the potential treatment of select hematologic malignancies. The SF3B1 program represents H3’s most advanced effort in its strategy to impact deregulated RNA homeostasis in cancer through RNA splicing modulation. The spliceosome is a complex molecular machine found in the nucleus of cells and is responsible for the removal of noncoding introns from a transcribed pre-mRNA. Recurrent heterozygous mutations in several core members (SF3B1, U2AF1, SRSF2, ZRSR2) of the spliceosome have been identified in various cancers and lead to aberrant mRNA splicing that may contribute to disease pathogenesis. H3 is building on its discoveries around targeting SF3B1 and splice modulation to design novel treatments for various cancers.
H3 Biomedicine Inc. Presents at BBC BD Boston, Mar-09-2016 01:00 PM
Jan 1 16
H3 Biomedicine Inc. Presents at BBC BD Boston, Mar-09-2016 01:00 PM. Venue: The Westin Copley Place, 10 Huntington Avenue, Boston, MA 02116, United States. Speakers: Marlus Warmuth.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries